TYK Medicines Inc. announced that its investigational Class 1 new drug, Asandeutertinib (TY-9591), has been included in the List of Products for Priority Review by the Center for Drug Evaluation of the National Medical Products Administration (NMPA) in China. The drug is proposed as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion or exon 21 (L858R) substitution mutation, including those with central nervous system metastases. The priority review status was granted in accordance with relevant regulatory requirements under the Administration Measures for Drug Registration and other related guidelines. No other beneficiary organizations were mentioned in the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260129-12004621), on January 29, 2026, and is solely responsible for the information contained therein.